Use of the EnLightTM and LightPathTM Imaging Systems in Gastrointestinal Tumour Surgery (CLIO)
Evaluation of the Use of Intra-operative Molecular Imaging With BetaScope and in Vitro Measurement With LightPath Specimen Analyser Devices in Gastrointestinal Tumour Surgery
This study will evaluate the performance of the EnLightTM and LightPathTM Imaging Systems in detecting tumour lesions in patients with gastric, pancreas, bile duct or duodenal cancer.
EnLightTM will be used to detect positron emission and the LightPathTM system to detect Cerenkov Luminescence. Both are emitted by the Positron Emission Tomography (PET) agent.
The study will also evaluate the patient safety and radiation safety of the EnLightTM, and the safety for the device operators and surgical staff of the LightPathTM Imaging System.
Přehled studie
Postavení
Detailní popis
This is a pilot study that is prospective, open-label, single-centre in nature in patients with gastric, pancreas, bile duct or duodenal cancer in whom tumour excision surgery is indicated.
Patients who give written informed consent will be screened for the study (Visit 1). Patients will undergo a positron emission tomography (PET) whole body scan. Screening assessments, including the PET scan, must be performed no less than 60 days before surgery and may be performed on the day of surgery.
On the day of surgery (Visit 2), subject's blood glucose level will be measured. Subjects with a blood glucose level < 12 mmol/l will receive an intravenous injection of 2-5 Mega Becquerel/kg (MBq/kg), up to a maximum 300 MBq of fluorine-18 fluorodeoxyglucose (18F-FDG) prior to surgery.
During surgery and not less than 120 minutes after injection of FDG, the primary lesion will be imaged using the EnLightTM system to determine margin status.
Gastrointestinal tumour excision surgery will then be performed according to standard of care. The surgical cavity and the lymph nodes will be imaged by the EnLightTM system to establish whether other radioactive tissue remain. These results will not influence any surgical or clinical decision-making, which will remain as standard of care. The resected tumour excision specimen will be imaged by the LightPathTM Imaging System. The resected tumour excision specimen will, in addition, be analysed according to standard of care pathology. The surgeon and surgical staff will be monitored for external exposure to ionizing radiation by means of dosimeters, and position sensors during surgery.
Patients will be followed-up (Visit 3) within a 2 - 14 day window after the end of surgery for adverse events (AEs). Those related to the use of the investigational devices, or the PET imaging agent will be identified as such.
Typ studie
Kontakty a umístění
Studijní místa
-
-
-
Budapest, Maďarsko
- Semmelweis University First Clinic of Surgery
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Metoda odběru vzorků
Studijní populace
Popis
Inclusion Criteria:
- Provides written informed consent to participate in the study.
- Is a man or woman aged ≥ 30 years.
- Patients diagnosed with gastric, pancreatic, bile duct or duodenal cancer whose treatment is to be tumour excision surgery.
- Life expectancy of at least 12 months.
- Blood glucose level < 12 mmol/l.
Exclusion Criteria:
- Participation in another clinical study either concurrently or within 180 days prior to surgery.
- Major surgery within 30 days before the baseline visit.
- Women who are pregnant or lactating.
- Renal impairment, hepatic impairment, serious infection or other life-threatening illness, other than cancer, within 60 days before surgery.
- Previous exposure to ionizing radiation >5 millisieverts (mSv) in the previous 12 months.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Observační modely: Jiný
- Časové perspektivy: Budoucí
Kohorty a intervence
Skupina / kohorta |
Intervence / Léčba |
|---|---|
|
EnLightTM and LightPathTM Imaging Systems arm
Patients will first be injected intravenously with 2-5 MBq/kg, up to a maximum 300 MBq of the marketed product 18F-fluorodeoxyglucose (FDG) and after this undergo tumour excision surgery according to standard of care. The surgical cavity will be imaged by the EnLightTM system and the tumour excision specimen will be imaged by both the EnLightTM and LightPathTM Imaging Systems. The EnLightTM and LightPathTM Imaging Systems results will not influence any surgical or clinical decision-making. The tumour excision specimen will be analysed according to standard of care pathology. Patients will be followed-up (Visit 3) 2-14 days after the end of surgery for adverse events (AEs). |
The FDG is injected at least 120 minutes prior to the imaging by the EnLightTM and LightPathTM Imaging Systems
Ostatní jména:
The surgical cavity and the resected lymph nodes (if any) will be imaged by the EnLightTM system to establish whether radioactive tissue remains after surgery.
The resected tumour excision specimens and the resected lymph nodes (if any)will be imaged by CLI and by WLI to establish whether they contain radioactive tissue.
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
The location of PET imaging agent as measured by beta particle detection
Časové okno: Intraoperatively (during the single session of surgery on Day 0)
|
The EnLightTM will be used for determining the number of lesions, their location and margin status, in the surgical cavity including within surrounding tissue, and lymph nodes.
The EnLightTM is a beta particle detector used for imaging the location of the PET imaging agent.
It works both in a hot-spot mode, to localise areas with high beta particle detection signal from the PET imaging agent, and in an imaging mode that allows video imaging of areas where the PET imaging agent has accumulated.
|
Intraoperatively (during the single session of surgery on Day 0)
|
|
The location of PET imaging agent as measured by the LightPathTM Imaging System
Časové okno: Intraoperatively (during the single session of surgery on Day 0)
|
The LightPathTM Imaging System will be used for determining the margin status of lesions and the metastatic involvement of lymph nodes.
|
Intraoperatively (during the single session of surgery on Day 0)
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
The number of lesions by histopathology
Časové okno: Expected on average Day 10 after surgery
|
Number of lesions according to standard of care histopathology.
|
Expected on average Day 10 after surgery
|
|
The number of metastatic lymph nodes by histopathology
Časové okno: Expected on average Day 10 after surgery
|
The number of metastatic lymph nodes according to standard of care histopathology.
|
Expected on average Day 10 after surgery
|
|
The extent of resection margins by histopathology
Časové okno: Expected on average Day 10 after surgery
|
Extent of resection margins according to standard of care histopathology.
|
Expected on average Day 10 after surgery
|
|
Ease of use measured by questionnaire
Časové okno: At the end of imaging on Day 0
|
Ease of use measured by study-specific questionnaire
|
At the end of imaging on Day 0
|
|
Radiation exposure
Časové okno: At the time of discharge to the ward after surgery on Day 0
|
Radiological dose in microsieverts as measured by dosimeters worn by operating room staff
|
At the time of discharge to the ward after surgery on Day 0
|
|
Number of participants with adverse events
Časové okno: Visit 3, at day 3-15
|
Patients will be followed-up until Visit 3, 2-14 days after the end of surgery on Day 0 for adverse events
|
Visit 3, at day 3-15
|
Spolupracovníci a vyšetřovatelé
Sponzor
Spolupracovníci
Vyšetřovatelé
- Ředitel studie: Sheryl O'Farrell, PhD, Head of Clinical Development
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia
Primární dokončení (Aktuální)
Dokončení studie
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhad)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Odhad)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
- Nemoci trávicího systému
- Novotvary podle histologického typu
- Novotvary
- Novotvary podle místa
- Adenokarcinom
- Karcinom
- Novotvary, žlázové a epiteliální
- Gastrointestinální onemocnění
- Střevní nemoci
- Střevní novotvary
- Duodenální onemocnění
- Nemoci žlučových cest
- Nemoci žlučových cest
- Novotvary žlučových cest
- Gastrointestinální novotvary
- Novotvary trávicího systému
- Cholangiokarcinom
- Novotvary žlučovodů
- Novotvary dvanáctníku
- Molekulární mechanismy farmakologického působení
- Radiofarmaka
- Fluordeoxyglukóza F18
Další identifikační čísla studie
- LPM-005
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
produkt vyrobený a vyvážený z USA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .